Jonathan Haydak

Jonathan Haydak

Auto-generated profile, based on publicly available information

Jonathan Haydak

Barbara T. Murphy Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2019 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
RVRoss J. Verploegh
Ross J. Verploegh
AKAmbarish Kulkarni
Ambarish Kulkarni
SBSalah Eddine Boulfelfel
Salah Eddine Boulfelfel
JHJonathan C. Haydak
Jonathan C. Haydak
DTDai Tang
Dai Tang
DSDavid S. Sholl
David S. Sholl

31 July 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
XGXuhua Ge
Xuhua Ge
TZTao Zhang
Tao Zhang
XYXiaoxia Yu
Xiaoxia Yu
AMAlecia N. Muwonge
Alecia N. Muwonge
NANanditha Anandakrishnan
Nanditha Anandakrishnan
EAEvren Azeloglu
Evren Azeloglu
Significance Statement: The functional basis of the spatial cytoskeletal organization in the kidney podocyte that gives rise to its unique interdigitating morphology has been elusive. An integrative approach identified a novel podocyte-specific actin-associated protein, LIM-nebulette, that brings vimentin intermediate filaments to actin microfilaments, promoting mechanical stability, by regulating focal adhesions, calcium dynamics, and Rho GTPase activity. Silencing of LIM-nebulette is associated with aberrant biophysical properties in human podocytes in culture as well as with multiple glomerulopathies in patients, at both the RNA transcript and protein levels. Background: Maintenance of the intricate interdigitating morphology of podocytes is crucial for glomerular filtration. One of the key aspects of specialized podocyte morphology is the segregation and organization of distinct cytoskeletal filaments into different subcellular components, for which the exact mechanisms remain poorly understood. Methods: Cells from rats, mice, and humans were used to describe the cytoskeletal configuration underlying podocyte structure. Screening the time-dependent proteomic changes in the rat puromycin aminonucleoside–induced nephropathy model correlated the actin-binding protein LIM-nebulette strongly with glomerular function. Single-cell RNA sequencing and immunogold labeling were used to determine Nebl expression specificity in podocytes. Automated high-content imaging, super-resolution microscopy, atomic force microscopy (AFM), live-cell imaging of calcium, and measurement of motility and adhesion dynamics characterized the physiologic role of LIM-nebulette in podocytes. Results: Nebl knockout mice have increased susceptibility to adriamycin-induced nephropathy and display morphologic, cytoskeletal, and focal adhesion abnormalities with altered calcium dynamics, motility, and Rho GTPase activity. LIM-nebulette expression is decreased in diabetic nephropathy and FSGS patients at both the transcript and protein level. In mice, rats, and humans, LIM-nebulette expression is localized to primary, secondary, and tertiary processes of podocytes, where it colocalizes with focal adhesions as well as with vimentin fibers. LIM-nebulette shRNA knockdown in immortalized human podocytes leads to dysregulation of vimentin filament organization and reduced cellular elasticity as measured by AFM indentation. Conclusions: LIM-nebulette is a multifunctional cytoskeletal protein that is critical in the maintenance of podocyte structural integrity through active reorganization of focal adhesions, the actin cytoskeleton, and intermediate filaments.

22 January 2024 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MYMiran Yoo
Miran Yoo
JHJonathan C. Haydak
Jonathan C. Haydak
EAEvren Azeloglu
Evren Azeloglu
KLKyung Lee
Kyung Lee
LGLuca Gusella
Luca Gusella
Significance Statement: The renal immune infiltrate observed in autosomal polycystic kidney disease contributes to the evolution of the disease. Elucidating the cellular mechanisms underlying the inflammatory response could help devise new therapeutic strategies. Here, we provide evidence for a mechanistic link between the deficiency polycystin-1 and mitochondrial homeostasis and the activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)/stimulator of the interferon genes (STING) pathway. Our data identify cGAS as an important mediator of renal cystogenesis and suggest that its inhibition may be useful to slow down the disease progression. Background: Immune cells significantly contribute to the progression of autosomal dominant polycystic kidney disease (ADPKD), the most common genetic disorder of the kidney caused by the dysregulation of the Pkd1 or Pkd2 genes. However, the mechanisms triggering the immune cells recruitment and activation are undefined. Methods: Immortalized murine collecting duct cell lines were used to dissect the molecular mechanism of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) activation in the context of genotoxic stress induced by Pkd1 ablation. We used conditional Pkd1 and knockout cGas −/− genetic mouse models to confirm the role of cGAS/stimulator of the interferon genes (STING) pathway activation on the course of renal cystogenesis. Results: We show that Pkd1-deficient renal tubular cells express high levels of cGAS, the main cellular sensor of cytosolic nucleic acid and a potent stimulator of proinflammatory cytokines. Loss of Pkd1 directly affects cGAS expression and nuclear translocation, as well as activation of the cGAS/STING pathway, which is reversed by cGAS knockdown or functional pharmacological inhibition. These events are tightly linked to the loss of mitochondrial structure integrity and genotoxic stress caused by Pkd1 depletion because they can be reverted by the potent antioxidant mitoquinone or by the re-expression of the polycystin-1 carboxyl terminal tail. The genetic inactivation of cGAS in a rapidly progressing ADPKD mouse model significantly reduces cystogenesis and preserves normal organ function. Conclusions: Our findings indicate that the activation of the cGAS/STING pathway contributes to ADPKD cystogenesis through the control of the immune response associated with the loss of Pkd1 and suggest that targeting this pathway may slow disease progression.

8 May 2025 in Biophysical Journal
Verified
Journal Article
Closed access
JHJonathan Haydak
Jonathan Haydak
EAEvren Azeloglu
Evren Azeloglu

16 August 2024 in Science Advances
Verified
Journal Article
Open access
SBSmiti Bhattacharya
Smiti Bhattacharya
AEAbora Ettela
Abora Ettela
JHJonathan Haydak
Jonathan Haydak
CHChad Hobson
Chad Hobson
ASAlan Stern
Alan Stern
EAEvren Azeloglu
Evren Azeloglu
Assays that measure morphology, proliferation, motility, deformability, and migration are used to study the invasiveness of cancer cells. However, native invasive potential of cells may be hidden from these contextual metrics because they depend on culture conditions. We created a micropatterned chip that mimics the native environmental conditions, quantifies the invasive potential of tumor cells, and improves our understanding of the malignancy signatures. Unlike conventional assays, which rely on indirect measurements of metastatic potential, our method uses three-dimensional microchannels to measure the basal native invasiveness without chemoattractants or microfluidics. No change in cell death or proliferation is observed on our chips. Using six cancer cell lines, we show that our system is more sensitive than other motility-based assays, measures of nuclear deformability, or cell morphometrics. In addition to quantifying metastatic potential, our platform can distinguish between motility and invasiveness, help study molecular mechanisms of invasion, and screen for targeted therapeutics.

8 September 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ADAbigail Daily
Abigail Daily
NANanditha Anandakrishnan
Nanditha Anandakrishnan
JHJonathan Haydak
Jonathan Haydak
JHJonathan Himmelfarb
Jonathan Himmelfarb
EAEvren Azeloglu
Evren Azeloglu
The US Food and Drug Administration Modernization Act and the federal policy changes in 2025 have signaled a shift toward the use of nonanimal, human-centered models for preclinical drug development and toxicity screening, emphasizing 3D cell-based, organ-on-chip, and organoid platforms as alternatives to animal models. While animal models have advanced our understanding of disease mechanisms, they do not allow decoupling of biomechanical and biochemical effects during pathogenesis. I n vitro systems offer improved accessibility but lack physiologically relevant microenvironments. In this review, we discuss how kidney-on-chip and induced pluripotent stem cell–derived kidney organoid models serve as physiologically relevant platforms for modeling nephrotoxicity, kidney development, and pathophysiology. Kidney-on-chip models recapitulate in vivo mechanical forces, such as fluid shear stress and mechanical strain, experienced by cells, enabling real-time functional readouts of glomerular filtration, tubular reabsorption, and nephrotoxic response. Integrating on-chip platforms with patient-derived induced pluripotent stem cells and differentiated kidney cell types allows human-relevant responses unavailable in static culture. Induced pluripotent stem cell–derived kidney organoids recapitulate the 3D architecture of nephron segments and ureteric bud branching patterns, demonstrating selective transport, toxicity responses, and structural stability over months in culture. We detail how bioengineering approaches, including organoid-on-chip models, bioprinting, and multi–organ-on-chip integration, could address the limitations of organoids, such as maturity, scalability, and vascularization. We discuss how integrating publicly available clinical databases and machine learning approaches with on-chip validation can improve translational relevance. We conclude that interdisciplinary collaboration between engineers, biologists, and physician scientists remains essential to translating bioengineered kidney models into clinical and therapeutic applications.